Dr Sylvia S Yedinsky, MD | |
A8-46 Equinox On The Battenkill, Manchester Village, VT 05254-1080 | |
(802) 362-1585 | |
Not Available |
Full Name | Dr Sylvia S Yedinsky |
---|---|
Gender | Female |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | A8-46 Equinox On The Battenkill, Manchester Village, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174782239 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 042-0007707 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Sylvia S Yedinsky, MD Po Box 1080, Manchester, VT 05254-1080 Ph: (802) 362-1585 | Dr Sylvia S Yedinsky, MD A8-46 Equinox On The Battenkill, Manchester Village, VT 05254-1080 Ph: (802) 362-1585 |
News Archive
A new study by investigators from Brigham and Women's Hospital, Harvard Medical School, and the Harvard T.H. Chan School of Public Health offers insights from a cohort study of women in the U.S. who reported consuming a Mediterranean-type diet.
HeartWare International, Inc. today announced that it has submitted a Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the HeartWare® Ventricular Assist System as a bridge to heart transplantation for patients with end-stage heart failure.
That men who have sex with men run a greater risk of HIV than others has been known since the virus was discovered. However a thesis from Karolinska Institutet now shows that it is a small sub-group of these men who account for the greater part of the risk increase.
A new study indicates that many donated organs that are discarded might be suitable for transplantation if certain steps are taken to limit damage following donation. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology.
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.
› Verified 9 days ago